Streetbeat News

Products Services

SOGP

Sound Group Inc. (NASDAQ:SOGP), a global audio-centric social and entertainment company, announced an upgrade to one of its AI-powered applications, introducing voice technology and the latest AI models.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:31 am

PMN

ProMIS Neurosciences has received patent approvals from the European Patent Office, Japanese Patent Office, and IP Australia for PMN310, a novel monoclonal antibody for Alzheimer's disease treatment. These patents cover the composition of matter and method of use for PMN310, which targets toxic oligomers of amyloid-beta, a key factor in Alzheimer's disease progression.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:19 am

CLDI

Calidi Biotherapeutics and City of Hope have received a $5.3M grant from the California Institute for Regenerative Medicine to advance their CLD-101 (Neuronova) treatment for ovarian cancer. This funding aims to support the development and potential commercialization of CLD-101, a promising therapeutic option for ovarian cancer patients.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:18 am

SILV

SilverCrest reported sales of 58,200 ounces of gold and 5.62 million ounces of silver, totaling 10.25 million ounces of silver equivalent (AgEq) in Q4. This indicates a significant production and sales achievement for the company.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:18 am

BRKR

Bruker Corporation announced advancements in its CCS-Enabled 4D-Proteomics TimsTOF solutions for immunopeptidomes and glycoproteomics at the US Human Proteome Organization Congress 2024. These developments are expected to enhance research capabilities in proteomics.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:17 am

CDT

Conduit Pharmaceuticals announced the opening of a new prime laboratory space in Cambridge, UK, marking a significant expansion for the company.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:16 am

NVCR

Novocure announced that an exploratory subgroup analysis of the Phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial has been selected for presentation at the European Society on Gynecological Oncology 2024 Congress. The analysis found that PLD-naïve patients receiving TTFields therapy and paclitaxel had a median overall survival of 16.0 months, compared to 11.7 months for those treated with paclitaxel alone.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:16 am

GLUE

Monte Rosa Therapeutics announced its first development candidate from the NEK7 program, MRT-8102, targeting inflammatory diseases driven by Interleukin-1β and the NLRP3 inflammasome.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:14 am

PERI

Perion Network Ltd. has announced a partnership with Way.io to enter the world's largest Digital Out-of-Home (DOOH) advertising market, valued at $5.2 billion. This strategic move aims to leverage Way.io's expertise and presence in the DOOH market to expand Perion's advertising capabilities and reach.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:12 am

TVTX

Travere Therapeutics has submitted a Supplemental New Drug Application (sNDA) to the FDA for full approval of FILSPARI, aimed at treating IgA Nephropathy. This step could mark a significant advancement in the treatment options available for this kidney disease.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:12 am